-
ViewGet more information about your protein expression conditions in less time with Andromeda
Get more information about your protein expression conditions in less time with Andromeda
-
ReadFor protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
The total protein degradation modality — locally and specifically targeting the disease-causing proteins and degrading their toxic aggregates — promises to be revolutionary. But the development of...
-
ReadWhy so many companies are betting on PROTACs as a superior therapeutic modality
One advantage of PROTACs is their unique mode of action — the induced proximity of an E3 ligase and the protein of interest (POI) triggers the ubiquitination and then degradation of the POI by the...
-
ReadProtein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
ReadIs your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
If you work in a drug discovery lab, at some point, you too may realize that the technologies at hand are limiting your ability to tackle all your screening projects. Here are 3 signs that it’s...
-
ReadFollow these 7 tips when pipetting small volumes to get consistent assay results
Here are some best practices that will improve your pipetting technique as well as guarantee successful assays and consistent results.
-
Loading more...
